Kolkata News Today

Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight

August 05
01:40 2021
Chemotherapy-Induced Hearing Loss Market Insight Report: Analysis of Epidemiology Segmentation, Treatment Landscape, Market Size, Emerging Drugs and Key Companies by DelveInsight

Chemotherapy-Induced Hearing Loss Market
The dynamics of the Chemotherapy-Induced Hearing Loss market are likely to change due to an increase in the incidence of solid tumors treated with chemotherapy during the forecast period of 2021-2030.

DelveInsight’s Chemotherapy-Induced Hearing Loss market report examines historical and projected epidemiology, as well as Chemotherapy-Induced Hearing Loss market trends in the 7MM (the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).

Some of the Key Highlights from the Chemotherapy-Induced Hearing Loss Market Report

  • 61% of patients globally had bilateral hearing loss. Hearing Loss was more common and severe in children treated for medulloblastoma, osteosarcoma, and neuroblastoma (Knight et al.).

  • As per DelveInsight analysis, Chemotherapy-Induced Hearing Loss affects young children more than adults.

  • Some of the key players at the global level active in the Chemotherapy-Induced Hearing Loss market are Fennec Pharmaceuticals, Matrix Biomed, Sensorion, Sound Pharmaceuticals, and others.

  • Pedmark (sodium thiosulfate) (Fennec Pharmaceuticals) is a cisplatin neutralizing agent in development for the prevention of hearing loss in pediatric cisplatin chemotherapy patients. In March 2018, the FDA granted sodium thiosulfate breakthrough therapy and fast track designation.

  • SENS-401 (Sensorion) is a novel drug candidate for the treatment of Sudden Sensorineural Hearing Loss (SSNHL). The FDA designated the drug as an orphan drug, and the European Medicines Agency approved a pediatric investigation plan (EMA).

Find out which key player is expected to be at the forefront of the Chemotherapy-Induced Hearing Loss Market by requesting sample @ Chemotherapy and Ear Infection

The Chemotherapy-Induced Hearing Loss market report covers current treatment practices, emerging drugs, individual Chemotherapy-Induced Hearing Loss therapy market share, and current and forecasted Chemotherapy-Induced Hearing Loss market size from 2018 to 2030, segmented by seven major markets.

Chemotherapy-Induced Hearing Loss: Overview

One of the most serious side effects of chemotherapy  (platinum compounds) is hearing loss. It is caused by the degeneration of ear hair cells, which are unable to regenerate because they lack the ability to self-renew. Platinum-induced hearing loss is typically bilateral, sensorineural, and permanent. The higher frequencies (>4000 Hz) are the first to be harmed, but even the lowest frequencies (500–4000 Hz), which are required to understand language, can be damaged over time.

Chemotherapy-Induced Hearing Loss Epidemiology Segmentation

The Chemotherapy-Induced Hearing Loss report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Chemotherapy-Induced Hearing Loss Incident Cases

  • Chemotherapy-Induced Hearing Loss Age-Specific Cases

  • Chemotherapy-Induced Hearing Loss Severity-Specific Cases

Chemotherapy-Induced Hearing Loss Treatment Landscape

The current major Chemotherapy-Induced Hearing Loss treatment options include:

  • Assistive devices

  • Cochlear implant

  • Otoprotective agents

  • Hearing Aid

Chemotherapy-Induced Hearing Loss Market 

The dynamics of the Chemotherapy-Induced Hearing Loss market are likely to change due to an increase in the incidence of solid tumors treated with chemotherapy during the forecast period of 2021-2030. The existing pipeline for Chemotherapy-Induced Hearing Loss is limited, but the launch of Pedmark, a late-stage product, has the potential to drive the Chemotherapy-Induced Hearing Loss market in the upcoming years.

Get a detailed analysis of chemotherapy-induced hearing loss market @ Chemotherapy-Induced Hearing Loss Market Research

Chemotherapy-Induced Hearing Loss Pipeline Therapies and Key Companies 

  • Pedmark: Fennec Pharmaceuticals

  • Tempol: Matrix Biomed

  • SENS-401: Sensorion

  • SPI-1005: Sound Pharmaceuticals

Table of Contents 

1.

Report Introduction

2.

Chemotherapy-Induced Hearing Loss: Market Overview at a Glance

3.

Executive Summary

4.

Disease Background and Overview: Chemotherapy-Induced Hearing Loss

5.

Organization

6.

Patient Journey

7.

KOL

8.

Case Study

9.

Chemotherapy-Induced Hearing Loss Epidemiology and Patient Population  

10.

Chemotherapy-Induced Hearing Loss: Country-wise Epidemiology

11.

Chemotherapy-Induced Hearing Loss Treatment & Medical Practices

12.

Chemotherapy-Induced Hearing Loss Emerging Therapies

13.

Pedmark: Fennec Pharmaceuticals

14.

Chemotherapy-Induced Hearing loss: Market Size

15.

Chemotherapy-Induced Hearing Loss Country-wise Market Analysis

16.

Chemotherapy-Induced Hearing Loss Unmet Needs

17.

Chemotherapy-Induced Hearing Loss Market Drivers

18.

Chemotherapy-Induced Hearing Loss Market Barriers

19.

Chemotherapy-Induced Hearing Loss Market Access

20.

Report Methodology

21.

DelveInsight Capabilities

22.

Disclaimer

23.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Chemotherapy-Induced Nausea and Vomiting Market

Get comprehensive historical and forecast analysis of Chemotherapy-Induced Nausea and Vomiting Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Camurus, LP Pharmaceuticals, Skye Bioscience, TALLC Corporation, Starton Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/